Our mission is to bring cleverly-designed medicine to patients with the most difficult to treat cancers, immune disorders and infectious diseases.
Corvus Pharmaceuticals is an immunology focused biopharmaceutical company developing drugs and antibodies that target the most critical elements of the tumor immunity axis.
Our seasoned team of biopharma industry leaders are dedicated to developing new medicines for patients in need. Their successful track record of discovering, developing and commercializing innovative therapies for patients with serious diseases includes inventors and scientists who developed the anti-cancer and auto-immune disease medicines, Rituxan (rituximab), Imbruvica (ibrutinib) and Zelboraf (vemurafenib).
Founded in 2014, Corvus has rapidly developed a deep pipeline of potentially breakthrough investigational medicines designed to be potent, selective and convenient to administer. The pipeline has been expanded through internal discovery and in-licensing and we have efficiently moved our investigational medicines into the clinic, where we are conducting intelligently-designed, rigorously-conducted clinical trials at leading institutions.
We believe in putting patients first. With that in mind, we report our preclinical and clinical data promptly and frequently at major scientific meetings, so our research can be used by others to advance medicine for the benefit of patients.
We are developing immunology focused medicines that target the most critical elements of the tumor immunity axis
Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases